Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Interferon Alfa-2b in Advanced Renal Cell Carcinoma
NCT00561912Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2007
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival. Started Oct 2007; status: terminated.
02
Drugs
decitabine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00561912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561912.